tiprankstipranks
Advertisement
Advertisement

DE:6BG Stock Latest News

Lytix Biopharma’s Ruxotemitide Combo Shows Promise in Tough Cancers at ASCO 2026
Company AnnouncementsLytix Biopharma’s Ruxotemitide Combo Shows Promise in Tough Cancers at ASCO 2026
6d ago
6BG
Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus
PremiumCompany Announcements
Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus
17d ago
6BG
Lytix Biopharma to Present Q1 2026 Results in Investor Webcast
PremiumCompany Announcements
Lytix Biopharma to Present Q1 2026 Results in Investor Webcast
22d ago
6BG
Lytix Biopharma Highlights New Phase II Data Suggesting Systemic Immune Effects of Cancer Drug
PremiumCompany Announcements
Lytix Biopharma Highlights New Phase II Data Suggesting Systemic Immune Effects of Cancer Drug
1M ago
6BG
Lytix Biopharma’s Lead Cancer Therapy Highlighted in ASCO 2026 Combination Study
PremiumCompany Announcements
Lytix Biopharma’s Lead Cancer Therapy Highlighted in ASCO 2026 Combination Study
2M ago
6BG
Lytix Biopharma Posts Durable Phase II Responses for Ruxotemitide Combo in Refractory Melanoma
PremiumCompany AnnouncementsLytix Biopharma Posts Durable Phase II Responses for Ruxotemitide Combo in Refractory Melanoma
2M ago
6BG
Lytix Biopharma Completes Conversion to Public Limited Company
Premium
Company Announcements
Lytix Biopharma Completes Conversion to Public Limited Company
2M ago
6BG
Lytix Biopharma Overhauls Board and Renews Capital Mandate at AGM
Premium
Company Announcements
Lytix Biopharma Overhauls Board and Renews Capital Mandate at AGM
2M ago
6BG
Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan
PremiumCompany Announcements
Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan
2M ago
6BG
Lytix Biopharma Appoints New COO to Drive Next Growth Phase
PremiumCompany Announcements
Lytix Biopharma Appoints New COO to Drive Next Growth Phase
2M ago
6BG
Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend
PremiumCompany Announcements
Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend
2M ago
6BG
Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise
PremiumCompany Announcements
Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise
2M ago
6BG
Lytix to Unveil Final Phase II Melanoma Data on Ruxotemitide at AACR 2026
PremiumCompany AnnouncementsLytix to Unveil Final Phase II Melanoma Data on Ruxotemitide at AACR 2026
3M ago
6BG
Lytix Biopharma Registers Share Capital Increase After NOK 16.3 Million Offering
Premium
Company Announcements
Lytix Biopharma Registers Share Capital Increase After NOK 16.3 Million Offering
3M ago
6BG
Lytix Biopharma’s Oncolytic Peptide Platform Gains Visibility with New JITC Review
Premium
Company Announcements
Lytix Biopharma’s Oncolytic Peptide Platform Gains Visibility with New JITC Review
4M ago
6BG
Lytix Biopharma Advances Ruxotemitide Program as Strong Phase II Data and Cost Discipline Mark 2025
PremiumCompany Announcements
Lytix Biopharma Advances Ruxotemitide Program as Strong Phase II Data and Cost Discipline Mark 2025
4M ago
6BG
Lytix Biopharma Raises NOK 16.3 Million in Subsequent Share Offering
PremiumCompany Announcements
Lytix Biopharma Raises NOK 16.3 Million in Subsequent Share Offering
4M ago
6BG
Lytix Biopharma’s NOK 30 Million Subsequent Share Offering Closes Today
PremiumCompany Announcements
Lytix Biopharma’s NOK 30 Million Subsequent Share Offering Closes Today
4M ago
6BG
Lytix Biopharma Schedules Webcast for Fourth-Quarter and Second-Half 2025 Results
PremiumCompany Announcements
Lytix Biopharma Schedules Webcast for Fourth-Quarter and Second-Half 2025 Results
4M ago
6BG
Lytix Biopharma Launches Subsequent Share Offering Following NOK 61 Million Private Placement
PremiumCompany AnnouncementsLytix Biopharma Launches Subsequent Share Offering Following NOK 61 Million Private Placement
4M ago
6BG
Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company
Premium
Company Announcements
Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company
4M ago
6BG
Lytix Biopharma Registers NOK 61 Million Private Placement, Expands Share Capital
Premium
Company Announcements
Lytix Biopharma Registers NOK 61 Million Private Placement, Expands Share Capital
5M ago
6BG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >